Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
- Trial name
- NCT00001499
- Testing
- paclitaxel, cisplatin, chest radiotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, NSCLC
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent…
- Trial name
- NCT01797471
- Testing
- Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Head and Neck Cancer, Lung Cancer
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer.
- Trial name
- NCT00019201
- Testing
- cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small Cell Lung Cancer, Individualized Radiation Dose Escalation
Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy
The aim of this present study is to test the feasibility and toxicity of individualized hypofractionated radiotherapy, and to report outcome data.
- Trial name
- IDEAL-VMAT (NCT01577212)
- Testing
- Individualized dose escalation
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Radboud University Medical Center
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A)…
- Trial name
- KEYVIBE-006 (NCT05298423)
- Testing
- pembrolizumab/vibostolimab, durvalumab, cisplatin
- Where
- 160 sites in United States, Argentina and 23 more
- Volunteers
- 610 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00945451
- Testing
- CK
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
NSCLC Stage III, SHR-1701
SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer
This randomized phase II exploratory clinical study aims to evaluate the efficacy and safety of SHR-1701 in patients with unresectable stage III non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC Stage III, SHR-1701, Chemoradiotherapy
- Trial name
- NCT07619911
- Testing
- SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy
- Volunteers
- 84 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer
PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer
The goal of this study is to find the maximum tolerable dose of radiation that can be delivered combined with chemotherapy (carboplatin \& paclitaxel) in patients with stage III non-small cell lung cancer (NSCLC).
- Trial name
- NCT03099577
- Testing
- radiochemotherapy 1, radiochemotherapy 2, radiochemotherapy 3
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell…
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01507428
- Testing
- 18F-Fluoromisonidazole, Carboplatin, Computed Tomography
- Where
- 31 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004160
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Alabama at Birmingham
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
- Trial name
- NCT04580498
- Testing
- SHR-1701+Paclitaxel+carboplatin, SHR-1701
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer
Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study
This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer.
- Trial name
- Isotoxic-IMRT (NCT01836692)
- Testing
- Intensity Modulated Radiotherapy treatment
- Where
- 7 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Prof Corinne Faivre-Finn
Non-small Cell Lung Cancer
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic…
- Trial name
- KEYNOTE-799 (NCT03631784)
- Testing
- Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage…
- Conditions
- Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer, EGFR Mutation-Related Tumors
- Trial name
- NCT04304638
- Testing
- radiation or chemo-radiation, EGFR-TKI Inhibitor
- Volunteers
- 450 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Cancer
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00547443
- Testing
- carboplatin, paclitaxel, sorafenib tosylate
- Where
- 2 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small-Cell-Lung Cancer
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal…
- Trial name
- CHER@NOS (NCT00463515)
- Testing
- carboplatin/gemcitabine, cisplatin/radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 77 people
- Sponsor
- University Hospital, Antwerp
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee…
- Trial name
- HORIZON 1 (NCT05170204)
- Testing
- Alectinib, Entrectinib, Durvalumab
- Where
- 45 sites in United States, Australia and 17 more
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Stage III Non-small Cell Lung Cancer, Unresectable Stage III NSCLC
In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy.
- Trial name
- PulmoPrint (NCT07653438)
- Testing
- Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Carcinoma, Non-Small-Cell Lung
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed Grade 2 and higher ILD and of disease progression in patients with…
- Trial name
- iDETECT (NCT04884269)
- Where
- 27 sites in Japan
- Volunteers
- 144 people
- Sponsor
- AstraZeneca